These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 19017726)

  • 1. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
    Toda T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
    Toda T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
    Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
    Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of dysferlin deficiency to skeletal muscle pathology in asymptomatic and severe dystroglycanopathy models: generation of a new model for Fukuyama congenital muscular dystrophy.
    Kanagawa M; Lu Z; Ito C; Matsuda C; Miyake K; Toda T
    PLoS One; 2014; 9(9):e106721. PubMed ID: 25198651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
    Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.
    Tachikawa M; Kanagawa M; Yu CC; Kobayashi K; Toda T
    J Biol Chem; 2012 Mar; 287(11):8398-406. PubMed ID: 22275357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. biAb Mediated Restoration of the Linkage between Dystroglycan and Laminin-211 as a Therapeutic Approach for α-Dystroglycanopathies.
    Gumlaw N; Sevigny LM; Zhao H; Luo Z; Bangari DS; Masterjohn E; Chen Y; McDonald B; Magnay M; Travaline T; Yoshida-Moriguchi T; Fan W; Reczek D; Stefano JE; Qiu H; Beil C; Lange C; Rao E; Lukason M; Barry E; Brondyk WH; Zhu Y; Cheng SH
    Mol Ther; 2020 Feb; 28(2):664-676. PubMed ID: 31843448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.
    Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T
    J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal glycosylation of dystroglycan in human genetic disease.
    Hewitt JE
    Biochim Biophys Acta; 2009 Sep; 1792(9):853-61. PubMed ID: 19539754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy.
    Yu M; He Y; Wang K; Zhang P; Zhang S; Hu H
    Hum Gene Ther; 2013 Mar; 24(3):317-30. PubMed ID: 23379513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.
    Beedle AM; Turner AJ; Saito Y; Lueck JD; Foltz SJ; Fortunato MJ; Nienaber PM; Campbell KP
    J Clin Invest; 2012 Sep; 122(9):3330-42. PubMed ID: 22922256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein.
    Vannoy CH; Xu L; Keramaris E; Lu P; Xiao X; Lu QL
    Hum Gene Ther Methods; 2014 Jun; 25(3):187-96. PubMed ID: 24635668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent Advances in α-dystroglycanopathy].
    Kuga A; Kanagawa M; Toda T
    Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.
    Kim J; Lana B; Torelli S; Ryan D; Catapano F; Ala P; Luft C; Stevens E; Konstantinidis E; Louzada S; Fu B; Paredes-Redondo A; Chan AE; Yang F; Stemple DL; Liu P; Ketteler R; Selwood DL; Muntoni F; Lin YY
    EMBO Rep; 2019 Nov; 20(11):e47967. PubMed ID: 31566294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.
    Longman C; Brockington M; Torelli S; Jimenez-Mallebrera C; Kennedy C; Khalil N; Feng L; Saran RK; Voit T; Merlini L; Sewry CA; Brown SC; Muntoni F
    Hum Mol Genet; 2003 Nov; 12(21):2853-61. PubMed ID: 12966029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zebrafish models for human FKRP muscular dystrophies.
    Kawahara G; Guyon JR; Nakamura Y; Kunkel LM
    Hum Mol Genet; 2010 Feb; 19(4):623-33. PubMed ID: 19955119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fukutin expression in mouse non-muscle somatic organs: its relationship to the hypoglycosylation of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.
    Saito Y; Yamamoto T; Ohtsuka-Tsurumi E; Oka A; Mizuguchi M; Itoh M; Voit T; Kato Y; Kobayashi M; Saito K; Osawa M
    Brain Dev; 2004 Oct; 26(7):469-79. PubMed ID: 15351084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
    Sudo A; Kanagawa M; Kondo M; Ito C; Kobayashi K; Endo M; Minami Y; Aiba A; Toda T
    Hum Mol Genet; 2018 Apr; 27(7):1174-1185. PubMed ID: 29360985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
    Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
    Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.